bevacizumab,panitumumab
roche,amgen
['rectal', 'colorectal', 'bevacizumab', 'panitumumab']
among patients with ras wild-type metastatic colorectal cancer, adding panitumumab, vs bevacizumab, to standard first-line chemotherapy significantly improved overall survival in patients with left-sided tumors and in the overall population. #aacr23
JAMA #Oncology is an international peer-reviewed journal and the definitive journal for scientists, clinicians, and trainees in the field of oncology.